When determining prior authorization criteria for a preferred drug class, the department shall consider the potential destabilizing effect on the recipient's health by any change in the recipient's established drug regimen, including, but not limited to, prescription drugs for human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), behavioral health, hemophilia, hepatitis C, biologic drugs, immunosuppressants and anticonvulsants.